Keywords: serevent, gains, child, asthma, indication, glaxo, subsidiary
SEREVENT GAINS CHILD ASTHMA INDICATION
Article | 08 February 1993
Glaxo subsidiary Allen & Hanburys' long-acting beta agonist Serevent (salmeterol xinafoate) has been licensed for treatment of asthmatic children over the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
